Logo

Predicine: Dennis Merkle

Jan 04, 2022

Dennis Merkle has been appointed as CEO of Predicine Europe and as the company's global head of biopharma business. He comes to Predicine from Invitae, where he led the oncology development strategy, alliance management, and biorepository teams. He joined Invitae as part of its acquisition of ArcherDx, where he was senior VP of corporate development. Prior to that, he built the global companion diagnostics group at Merck KGaA and held senior positions in marketing and R&D at Merck KGaA, Abbott Laboratories, and Philips.

Breaking News
The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.